Helicobacter pylori and Gastroesophageal Reflux Disease: To Treat or Not to Treat?

References

• Quigley EMM. Gastroesophageal reflux disease: the role of motility in pathophysiology and therapy. Am J Gastroenterol 1993;88:1649–51.
   PubMedGoogle Scholar
• Kuipers EJ, Uyterlinde AM, Pena AS, Hazenberg HJA, Bloemena E, Lindeman J, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995;90:1401–6.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Morrow S, Peacock R, Gillon K, Walan A, Bardhan K, et al. Changing patterns of H. pylori gastritis in long-standing acid suppression. Gut 1999;44 Suppl 1:A117.
   Google Scholar
• Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442–7.
   PubMed Web of Science ®Google Scholar
• Verdu EF, Armstrong D, Frazer R, Viani F, Idstrom J-P, Cederberg C, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539–43.
   Google Scholar
• Blaser MJ. In a world of black and white, Helicobacter pylori is gray. Ann Intern Med 1999;130:695–7.
   PubMedGoogle Scholar
• O’Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease—clinical implications and management. Aliment Pharmacol Ther 1999;13:117–27.
   PubMedGoogle Scholar
• Borkent MV, Beker JA. Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine. Gut 1988;29:385–9.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Bardhan KD, Wrangstadh M, Dixon MF, Brown L, Axon ATR. Does eradication of Helicobacter pylori influence the recurrence of symptoms in patients with symptomatic gastrooesophageal reflux disease? A randomised double blind study. Gut 1999;44 Suppl 1:A112.
   PubMedGoogle Scholar
• Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999;13:915–20.
   Google Scholar
• Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990;50:4737–40.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Lundell L, Klinkenberg-Knol EG, Havu N, Festen HPM, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018–22.
   Google Scholar
• Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997;41:740–7.
   Google Scholar
• Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997;112: 707–17.
   Google Scholar
• Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999;117:319–26.
   PubMed Web of Science ®Google Scholar
• Genta RM. Atrophy, acid suppression and Helicobacter pylori infection: a tale of two studies. Eur J Gastroenterol Hepatol 1999;11 Suppl 2:S29–33.
   Google Scholar
• Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525–8.
   PubMed Web of Science ®Google Scholar
• Solcia E, Fiocca R, Villani L, Carlsson J, Rudback A, Zeijlon L. Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. Scand J Gastroenterol 1996;31 Suppl 215:105–10.
   Google Scholar
• El-Nujumi A, Williams C, Ardill JE, Oien K, McColl KEL. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment. Gut 1998;42: 159–65.
   Google Scholar
• Schenk BE, Kuipers EJ, Nelis GF, Thijs JC, Bloemena E, Snel P, et al. H. pylori eradication for chronic gastritis during omeprazole therapy for GERD. Gastroenterology 1998;114 Suppl:A279.
   Google Scholar
• El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998;43:327–33.
   Google Scholar
• Werdmuller BFM, Loffeld RJLF. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997;42:103–5.
   PubMed Web of Science ®Google Scholar
• Hackelsberger A, Schultze V, Gunther T, von Arnim U, Manes G, Malfertheiner P. The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: a case-control study. Eur J Gastroenterol Hepatol 1998;10: 465–8.
   Google Scholar
• Vicari JJ, Peek RM, Falk GW, Goldblum JR, Easley KA. Schnell J, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115: 50–7.
   PubMed Web of Science ®Google Scholar
• Schenk BE, Kuipers EJ, Klinkenberg-Knol EG, Eskes SA, Meuwissen SGM. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999;94:884–7.
   PubMedGoogle Scholar
• Manes G, Mosca S, Lacetti M, Lioniello M, Balzano A. Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease. Scand J Gastroenterol 1999;34: 658–62.
   Google Scholar
• El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM. Corpus gastritis is protective against reflux oesophagitis. Gut 1999;45:181–5.
   Google Scholar
• Graham DY, Yamaoka Y. H. pylori and cagA: relationships with gastric cancer, duodenal ulcer and reflux esophagitis and its complications. Helicobacter 1998;3: 145–51.
   PubMed Web of Science ®Google Scholar
• Haruma K, Mihara M, Okamoto E, Kusunoki H, Hananoki M, Tanaka S, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus—evaluation of 24-h pH monitoring. Aliment Pharmacol Ther 1999;13:155–62.
   PubMed Web of Science ®Google Scholar
• Awad R, Comacho S, Toriz A, Bernal F, Abdo M. Is there a role for Helicobacter pylori in gastroesophageal reflux disease? A 24 hour ambulatory combined pH and manometry study. Gastroenterology 1997;112 Suppl:A62.
   Google Scholar
• Leodolter A, Dominguez-Munoz JE, Gerards C, Hackelsberger A, Malfertheiner P. Impact of Helicobacter pylori infection on gastroesophageal reflux. Gastroenterology 1998;114 Suppl: A200.
   Google Scholar
• Manes G, Bove A, Mosca S, Balzano A. Manometric and pH- metric findings in GERD with and without H. pylori infection. Gut 1998;43 Suppl 2:A110.
   Google Scholar
• Oberg S, Peters JH, Nigro JJ, Theisen J, Hagen JA, De Meester SR, et al. Helicobacter pylori is not associated with the manifestations of gastroesophageal reflux disease. Arch Surg 1999;134:722–6.
   Google Scholar
• Goh K-L, Parasakthi N, Cheah P-L, Prabhakeran R, Chin S-C. No occurrence of reflux oesophagitis following Helicobacter pylori eradication in duodenal ulcer patients—a 5 year endoscopic follow-up in South-East Asian patients. Gastroenterology 1999;116 Suppl:A173.
   Google Scholar
• Di Mario F, Dal Bo N, Salandin S, Buda A, Pilotto A, Kusstatscher S, et al. The appearance of GORD in patients with duodenal ulcer after eradication of Helicobacter pylori (Hp) infection: a 4-year prospective study. Gut 1998;43 Suppl 2: A95–6.
   Google Scholar
• Kang JY, Ho KY. Different prevalences of reflux oesophagitis and hiatus hernia among dyspeptic patients in England and Singapore. Eur J Gastroenterol Hepatol 1999;11:845–50.
   PubMedGoogle Scholar
• Neumann CS, Cooper BT. Ethnic differences in gastro- oesophageal reflux disease. Eur J Gastroenterol Hepatol 1999;11:735–9.
   PubMedGoogle Scholar
• Malfertheiner P, Veldhuyzen van Zanten S, Dent J, Bayerdorffer E, Lind T, O’Morain C, et al. Does cure of Helicobacter pylori infection induce heartburn? Gastroenterology 1998;114 Suppl: A212.
   Google Scholar
• Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E, Havu N, et al. No increase of reflux symptoms or esophagitis in patients with nonulcer dyspepsia 12 months after Helicobacter pylori eradication. A randomised double-blind placebocontrolled trial. Gastroenterology 1998;114 Suppl:A306.
   Google Scholar
• Flook D, Stoddard CJ. Gastro-oesophageal reflux and oesophagitis before and after vagotomy for duodenal ulcer. Br J Surg 1985;72:804–7.
   PubMedGoogle Scholar
• Bateson MC, Bouchier IAD. The association of oesohagitis with disease in the stomach and duodenum. Postgrad Med J 1981;57:217–8.
   PubMedGoogle Scholar
• Boyd EJ. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol 1996;91:1539–43.
   PubMed Web of Science ®Google Scholar
• O’Connor HJ, McGee C, Mehana N, Cunnane K. Prevalence of gastrooesophageal reflux disease (GORD) in H. pylori-positive peptic ulcer disease and the impact of eradication therapy. Endoscopy 1997;29:ElS.
   Google Scholar
• McColl KEL, Dickson A, El-Nujumi A, El-Omar E, Kelman A. Symptomatic benefit 1–3 years post H. pylori eradication in ulcer patients: impact of reflux disease. Gut 1999;44 Suppl 1: A120.
   Google Scholar
• McNamara D, Hamilton H, Beattie S, O’Morain C. Duodenal ulcer and GORD: unmasking the truth. Gut 1999;45 Suppl 3: A84.
   Google Scholar
• Manes G, Abagnale G, Riccio G, Lioniello M, Mosca S, Balzano A. GERD symptoms preexist and do not appear after H. pylori eradication for duodenal ulcer. Gut 1999;45 Suppl 3:A2.
   Google Scholar
• Chow W-H, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58: 588–90.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Taillon D, Burns RG, Vasudeva R, Howden CW, Demian SE. Is Helicobacter pylori (HP) associated with adenocarcinoma (AC) of the esophagus? Gastroenterology 1997;112 Suppl:A653.
   Google Scholar
• Henihan RDJ, Stuart RC, Nolan N, Gorey TF, Hennessy TPJ, O’Morain CA. Barrett’s esophagus and the presence of Helicobacter pylori. Am J Gastroenterol 1998;93:542–6.
   PubMedGoogle Scholar
• Quddus MR, Henley JD, Sulaiman RA, Palumbo TC, Gnepp DR. Helicobacter pylori infection and adenocarcinoma arising in Barrett’s esophagus. Hum Pathol 1997;28:1007–9.
   Google Scholar
• Torrado J, Ruiz B, Garay J, Asenjo JLG, Tovar JA, Cosme A, et al. Bloodgroup phenotypes, sulfomucins and Helicobacter pylori in Barrett’s esophagus. Am J Surg Pathol 1997;21:1023–9.
   PubMedGoogle Scholar
• Wright TA, Myskow M, Kingsnorth AN. Helicobacter pylori colonization of Barrett’s esophagus and its progression to cancer. Dis Esophagus 1997;10:196–200.
   Google Scholar
• Houck JA, Lucas JG. Absence of Campylobacter-like organisms in Barrett’s esophagus. Arch Pathol Lab Med 1989;113:470–2.
   PubMedGoogle Scholar
• Trakal E, Ortiz GA, Butti ALL, Armando RSR. Organismos tipo Campylobacter en el esofago de Barrett. Acta Gastroent Latinoamer 1987;17;85–96.
   PubMedGoogle Scholar
• Abbas Z, Hussainy AS, lbrahim F, Jafri SMW, Shaikh H, Khan AH. Barrett’s oesophagus and Heliciobacter pylori. J Gastroenterol Hepatol 1995;10:331–3.
   PubMedGoogle Scholar
• Csendes A, Smok G, Cerda G, Burdiles P, Mazza D, Csendes P. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett’s esophagus. Dis Esophagus 1997;10:38–42.
   PubMedGoogle Scholar
• Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesphagitis and Barrett’s oesophagus. Gut 1997;40:9–13.
   PubMed Web of Science ®Google Scholar
• de Mas C-R, Kramer M, Seifert E, Rippin G, Vieth M, Stolte M. Short Barrett: prevalence and risk factors. Scand J Gastroenterol 1999;34:1065–70.
   PubMedGoogle Scholar
• Young MA, Kim R, Clark MR, Van Bibber MM, Safatle- Ribeiro AV, Ribeiro U, et al. The incidence of premalignant markers of esophageal cancer is increased in Barrett’s patients with Helicobacter pylori (Hp). Gastroenterology 1996;110 Suppl:A618.
   Google Scholar
• Voutilainen M, Farkkila M, Juhola M, Mecklin J-P, Sipponen P, and The Central Finland Endoscopy Study Group. Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis. Gut 1999;45:644–8.
   Google Scholar
• Voutilainen M, Farkkila M, Mecklin J-P, Juhola M, Sipponen P. Chronic inflammation at the gastroesophageal junction (carditis) appears to be a specific finding related to Helicobacter pylori infection and gastroesophageal reflux disease. Am J Gastroenterol 1999;94:3175–80.
   Google Scholar
• Bowrey DJ, Clark GWB, Williams GT. Patterns of gastritis in patients with gastro-oesophageal reflux disease. Gut 1999;45:798–803.
   Google Scholar
• Cederberg C, Thomson ABR, Mahachai V, Westin J-A, Kirdeikis P, Fisher D, et al. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992;103: 913–8.
   Google Scholar
• Cederberg C, Rohss K, Lundborg P, Olbe L. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993;28:179–84.
   PubMed Web of Science ®Google Scholar
• Labenz J, Tillenburg B, Peitz U, Idstrom J-P, Verdu EF, Stolte M, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110:725–32.
   Google Scholar
• Labenz J, Tillenburg B, Peitz U, Borsch G, Idstrom JP, Verdu E, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997;92:576–81.
   PubMed Web of Science ®Google Scholar
• Koop H, Kuly S, Flug M, Eissle R, Monnikes H, Rose K, et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol 1996;8:915–8.
   PubMed Web of Science ®Google Scholar
• Carlsson R, Bate C, Dent J, Frisen L, Gnarpe H, Hallerback B, et al. Does H. pylori infection influence the response to treatment with acid inhibition in patients with gastroesophageal reflux disease (GERD)? Scand J Gastroenterol 1997;32 Suppl 224:F70.
   PubMedGoogle Scholar
• Holtman G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux oesophagitis during treatment with the proton-pump inhibitor pantoprazole. Gastroenterology 1999;117:11–16.
   Google Scholar
• Adamek RJ, Wenzel C, Behrendt J. Relapse prevention in reflux esophagitis with regard to HP-status: double-blind, randomized multicenter trial to compare the effectiveness of pantoprazole versus ranitidine. Gastroenterology 1999;116 Suppl:A108.
   Google Scholar
• Peters FTM, Kuipers EJ, Ganesh S, Sluiter WJ, Klinkenberg- Knol EC, Lamers CBHW, et al. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999;13:921–6.
   Google Scholar
• McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996;38:481–6.
   PubMed Web of Science ®Google Scholar
• Graham DY. Helicobacter pylori, GERD, NSAIDs and cancer: where we really stand. Am J Gastroenterol 1999;94:1420–21
   PubMedGoogle Scholar
• Axon ATR, Forman D. Helicobacter gastroduodenitis: a serious infectious disease. Br Med J 1997;314:1430–1.
   PubMedGoogle Scholar